The role of SET domain containing lysine methyltransferase 7 in tumorigenesis and development

References

• Luo M. Chemical and biochemical perspectives of protein lysine methylation. Chem Rev. 2018;118(14):6656–6705.
   PubMed Web of Science ®Google Scholar
• Hamamoto R, Saloura V, Nakamura Y. Critical roles of non-histone protein lysine methylation in human tumorigenesis. Nat Rev Cancer. 2015;15(2):110–124.
   PubMed Web of Science ®Google Scholar
• Husmann D, Gozani O. Histone lysine methyltransferases in biology and disease. Nat Struct Mol Biol. 2019;26(10):880–889.
   PubMed Web of Science ®Google Scholar
• Carlson SM, Gozani O. Nonhistone lysine methylation in the regulation of cancer pathways. Cold Spring Harb Perspect Med. 2016;6(11):a026435.
   PubMed Web of Science ®Google Scholar
• Batista IAA, Helguero LA. Biological processes and signal transduction pathways regulated by the protein methyltransferase SETD7 and their significance in cancer. Signal Transduct Target Ther. 2018;3(1):19.
   PubMed Web of Science ®Google Scholar
• Wilson JR, Jing C, Walker PA, et al. Crystal structure and functional analysis of the histone methyltransferase SET7/9. Cell. 2002;111(1):105–115.
   PubMed Web of Science ®Google Scholar
• Qian C, Zhou MM. SET domain protein lysine methyltransferases: structure, specificity and catalysis. Cell Mol Life Sci. 2006;63(23):2755–2763.
   PubMed Web of Science ®Google Scholar
• Xiao B, Jing C, Wilson JR, et al. Structure and catalytic mechanism of the human histone methyltransferase SET7/9. Nature. 2003;421(6923):652–656.
   PubMed Web of Science ®Google Scholar
• Ibanez G, McBean JL, Astudillo YM, et al. An enzyme-coupled ultrasensitive luminescence assay for protein methyltransferases. Anal Biochem. 2010;401(2):203–210.
   PubMed Web of Science ®Google Scholar
• Liu H, Li Z, Yang Q, et al. Substrate docking–mediated specific and efficient lysine methylation by the SET domain–containing histone methyltransferase SETD7. J Biol Chem. 2019;294(36):13355–13365.
   PubMed Web of Science ®Google Scholar
• Keating ST, El-Osta A. Transcriptional regulation by the Set7 lysine methyltransferase. Epigenetics. 2013;8(4):361–372.
   PubMed Web of Science ®Google Scholar
• Cornett EM, Ferry L, Defossez PA, et al. Lysine methylation regulators moonlighting outside the epigenome. Mol Cell. 2019;75(6):1092–1101.
   PubMed Web of Science ®Google Scholar
• Wang H, Cao R, Xia L, et al. Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase. Mol Cell. 2001;8(6):1207–1217.
   PubMed Web of Science ®Google Scholar
• Nishioka K, Chuikov S, Sarma K, et al. Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes Dev. 2002;16(4):479–489.
   PubMed Web of Science ®Google Scholar
• Akiyama Y, Koda Y, Byeon SJ, et al. Reduced expression of SET7/9, a histone mono-methyltransferase, is associated with gastric cancer progression. Oncotarget. 2016;7(4):3966–3983.
   PubMedGoogle Scholar
• Knutson SK, Warholic NM, Wigle TJ, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A. 2013;110(19):7922–7927.
   PubMed Web of Science ®Google Scholar
• McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012;492(7427):108–112.
   PubMed Web of Science ®Google Scholar
• Daigle SR, Olhava EJ, Therkelsen CA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013;122(6):1017–1025.
   PubMed Web of Science ®Google Scholar
• Shen C, Wang D, Liu X, et al. SET7/9 regulates cancer cell proliferation by influencing β-catenin stability. Faseb J. 2015;29(10):4313–4323.
   PubMed Web of Science ®Google Scholar
• Dhayalan A, Kudithipudi S, Rathert P, et al. Specificity analysis-based identification of new methylation targets of the SET7/9 protein lysine methyltransferase. Chem Biol. 2011;18(1):111–120.
   PubMedGoogle Scholar
• Zhou YH, Xia J, Xu WH, et al. Cullin-1 promotes cell proliferation in human breast cancer and is related to diabetes. Int J Biol Markers. 2016;31(4):e375–e381.
   PubMed Web of Science ®Google Scholar
• Michail O, Moris D, Theocharis S, et al. Cullin-1 and -2 protein expression in colorectal cancer: correlation with clinicopathological variables. Vivo. 2018;32(2):391–396 .
   PubMed Web of Science ®Google Scholar
• Kim SK, Lee H, Han K, et al. SET7/9 methylation of the pluripotency factor LIN28A is a nucleolar localization mechanism that blocks let-7 biogenesis in human ESCs. Cell Stem Cell. 2014;15(6):735–749.
   PubMed Web of Science ®Google Scholar
• Balzeau J, Menezes MR, Cao S, et al. The LIN28/let-7 pathway in cancer. Front Genet. 2017;8:31.
   PubMed Web of Science ®Google Scholar
• Wang T, He Y, Zhu Y, et al. Comparison of the expression and function of Lin28A and Lin28B in colon cancer. Oncotarget. 2016;7(48):79605–79616.
   PubMedGoogle Scholar
• Elkouris M, Kontaki H, Stavropoulos A, et al. SET9-Mediated regulation of TGF-β signaling links protein methylation to pulmonary fibrosis. Cell Rep. 2016;15(12):2733–2744.
   PubMed Web of Science ®Google Scholar
• Troncone E, Monteleone G. Smad7 and colorectal carcinogenesis: a double-edged sword. Cancers (Basel). 2019;11(5):612.
   PubMed Web of Science ®Google Scholar
• Zhang WJ, Wu XN, Shi TT, et al. Regulation of transcription factor Yin Yang 1 by SET7/9-mediated lysine methylation. Sci Rep. 2016;6(1):21718.
   PubMedGoogle Scholar
• Si W, Zhou J, Zhao Y, et al. SET7/9 promotes multiple malignant processes in breast cancer development via RUNX2 activation and is negatively regulated by TRIM21. Cell Death Dis. 2020;11(2):151.
   PubMed Web of Science ®Google Scholar
• Gu Y, Wang X, Liu H, et al. SET7/9 promotes hepatocellular carcinoma progression through regulation of E2F1. Oncol Rep. 2018;40(4):1863–1874.
   PubMed Web of Science ®Google Scholar
• Guo T, Wen XZ, Li ZY, et al. ISL1 predicts poor outcomes for patients with gastric cancer and drives tumor progression through binding to the ZEB1 promoter together with SETD7. Cell Death Dis. 2019;10(2):33.
   PubMedGoogle Scholar
• Oudhoff MJ, Braam MJS, Freeman SA, et al. SETD7 controls intestinal regeneration and tumorigenesis by regulating Wnt/β-Catenin and Hippo/YAP signaling. Dev Cell. 2016;37(1):47–57.
   PubMed Web of Science ®Google Scholar
• Montenegro MF, Sanchez-Del-Campo L, Gonzalez-Guerrero R, et al. Tumor suppressor SET9 guides the epigenetic plasticity of breast cancer cells and serves as an early-stage biomarker for predicting metastasis. Oncogene. 2016;35(47):6143–6152.
   PubMed Web of Science ®Google Scholar
• Song H, Chu JW, Park SC, et al. Isoform-specific lysine methylation of RORalpha2 by SETD7 is required for association of the TIP60 coactivator complex in Prostate cancer progression. Int J Mol Sci. 2020;21(5):1622.
   PubMed Web of Science ®Google Scholar
• Hong X, Huang H, Qiu X, et al. Targeting posttranslational modifications of RIOK1 inhibits the progression of colorectal and gastric cancers. Elife. 2018;7. DOI:10.7554/eLife.29511
   Web of Science ®Google Scholar
• Zhang SL, Du X, Tan LN, et al. SET7 interacts with HDAC6 and suppresses the development of colon cancer through inactivation of HDAC6. Am J Transl Res. 2020;12(2):602–611.
   PubMed Web of Science ®Google Scholar
• Cao L, Ren Y, Guo X, et al. Downregulation of SETD7 promotes migration and invasion of lung cancer cells via JAK2/STAT3 pathway. Int J Mol Med. 2020;45(5):1616–1626.
   PubMed Web of Science ®Google Scholar
• Lenstra DC, Damen E, Leenders RGG, et al. Structure-activity relationship studies on (R)-PFI-2 analogues as inhibitors of histone lysine methyltransferase SETD7. ChemMedchem. 2018;13(14):1405–1413.
   PubMed Web of Science ®Google Scholar
• Niu Y, Shi D, Li L, et al. Revealing inhibition difference between PFI-2 enantiomers against SETD7 by molecular dynamics simulations, binding free energy calculations and unbinding pathway analysis. Sci Rep. 2017;7(1):46547.
   PubMedGoogle Scholar
• Barsyte-Lovejoy D, Li F, Oudhoff MJ, et al. (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells. Proc Natl Acad Sci U S A. 2014;111(35):12853–12858.
   PubMed Web of Science ®Google Scholar
• Takemoto Y, Ito A, Niwa H, et al. Identification of cyproheptadine as an inhibitor of SET domain containing lysine methyltransferase 7/9 (Set7/9) that regulates Estrogen-dependent transcription. J Med Chem. 2016;59(8):3650–3660.
   PubMed Web of Science ®Google Scholar
• Gauthier N, Caron M, Pedro L, et al. Development of homogeneous nonradioactive methyltransferase and demethylase assays targeting histone H3 lysine 4. J Biomol Screen. 2012;17(1):49–58.
   PubMedGoogle Scholar
• Hou Z, Min W, Zhang R, et al. Lead discovery, chemical optimization, and biological evaluation studies of novel histone methyltransferase SET7 small-molecule inhibitors. Bioorg Med Chem Lett. 2020;30(9):127061.
   PubMed Web of Science ®Google Scholar